BOSTON– Cycle Pharmaceuticals Limited (Cycle) is proud to announce the launch of ORMALVI™ (dichlorphenamide) tablets, as a treatment option for patients with hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP) and related variants, approved by the US Food and Drug Administration (FDA).1
PPP is thought to affect about 5,000 people in the US.2
ORMALVI™ is being launched in partnership between Cycle and Torrent Pharma Inc. (Torrent).
ORMALVI™ is a treatment option that allows patients with PPP to remain on dichlorphenamide whilst accessing Cycle Vita™, a dedicated support platform that provides individualized product support* for patients.
“Patients with PPP typically have a difficult journey to diagnosis. It can take years and involve numerous studies and misdiagnoses. We’re fully aware of the unique challenges patients face with this rare disorder. We want to provide them with the support that they require to effectively manage their PPP. That’s why we’re providing individualized support, including a Bridge Program*, Co-pay Assistance Program* and a Patient Nutrition Program* tailored to the patient’s type of PPP and known triggers, to reinforce their clinic’s nutrition plan,” says Chikai Lai, SVP & Chief Commercial Officer, Cycle.
